141 related articles for article (PubMed ID: 29641561)
21. Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.
Kulkarni R; Feng JY; Miller MD; White KL
Antiviral Res; 2014 Jan; 101():131-5. PubMed ID: 24291780
[TBL] [Abstract][Full Text] [Related]
22. Tenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract.
Rodriguez-Garcia M; Patel MV; Shen Z; Bodwell J; Rossoll RM; Wira CR
Sci Rep; 2017 Apr; 8():45725. PubMed ID: 28368028
[TBL] [Abstract][Full Text] [Related]
23. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
[TBL] [Abstract][Full Text] [Related]
24. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
Phillips TK; Sinxadi P; Abrams EJ; Zerbe A; Orrell C; Hu NC; Brittain K; Gomba Y; Norman J; Wiesner L; Myer L; Maartens G
J Acquir Immune Defic Syndr; 2019 Jul; 81(3):311-318. PubMed ID: 30893125
[TBL] [Abstract][Full Text] [Related]
25. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
[TBL] [Abstract][Full Text] [Related]
26. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
Miller MD; Margot NA; Lamy PD; Fuller MD; Anton KE; Mulato AS; Cherrington JM
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):450-8. PubMed ID: 11511821
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.
Samuel R; Julian MN; Paredes R; Parboosing R; Moodley P; Singh L; Naidoo A; Gordon M
J Acquir Immune Defic Syndr; 2016 Dec; 73(4):384-389. PubMed ID: 27327263
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of adenine nucleotide converting enzymes in mitochondrial intermembrane space: a potential role of adenylate kinase isozyme 2 in neutrophil differentiation.
Tanimura A; Horiguchi T; Miyoshi K; Hagita H; Noma T
PLoS One; 2014; 9(2):e89916. PubMed ID: 24587121
[TBL] [Abstract][Full Text] [Related]
29. Gene structures of three vertebrate adenylate kinase isozymes.
Nakazawa A; Yamada M; Tanaka H; Shahjahan M; Tanabe T
Prog Clin Biol Res; 1990; 344():495-514. PubMed ID: 2168054
[TBL] [Abstract][Full Text] [Related]
30. Cloning and expression of human adenylate kinase 2 isozymes: differential expression of adenylate kinase 1 and 2 in human muscle tissues.
Lee Y; Kim JW; Lee SM; Kim HJ; Lee KS; Park C; Choe IS
J Biochem; 1998 Jan; 123(1):47-54. PubMed ID: 9504408
[TBL] [Abstract][Full Text] [Related]
31. Tenofovir resistance in early and long-term treated patients on first-line antiretroviral therapy in eight low-income and middle-income countries.
Inzaule SC; Jordan MR; Cournil A; Girón-Callejas A; Avila-Rios S; Mulenga L; Ssemwanga D; Asio J; Diop-Ndiaye H; Niasse-Traore F; Nhan DT; Dat VQ; Aghokeng AF; Billong S; Cham F; Doherty M; Bertagnolio S;
AIDS; 2020 Nov; 34(13):1965-1969. PubMed ID: 32694410
[TBL] [Abstract][Full Text] [Related]
32. Surveillance of transmitted resistance to antiretroviral drug classes among young children in the Western Cape Province of South Africa.
van Zyl GU; Cotton MF; Claassen M; Abrahams C; Preiser W
Pediatr Infect Dis J; 2010 Apr; 29(4):370-1. PubMed ID: 19935449
[TBL] [Abstract][Full Text] [Related]
33. Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
Silver N; Paynter M; McAllister G; Atchley M; Sayir C; Short J; Winner D; Alouani DJ; Sharkey FH; Bergefall K; Templeton K; Carrington D; Quiñones-Mateu ME
AIDS Res Ther; 2018 Nov; 15(1):18. PubMed ID: 30409215
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.
Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Chaipung B; Worrajittanon D; Leethochawalit M; Chiamwongpaet S; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Curlin ME; Holtz TH; Samandari T; Choopanya K;
Lancet HIV; 2017 Feb; 4(2):e59-e66. PubMed ID: 27866873
[TBL] [Abstract][Full Text] [Related]
35. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL
PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147
[TBL] [Abstract][Full Text] [Related]
36. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
[TBL] [Abstract][Full Text] [Related]
37. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
Kagan RM; Merigan TC; Winters MA; Heseltine PN
Antivir Ther; 2004 Oct; 9(5):827-8. PubMed ID: 15535422
[No Abstract] [Full Text] [Related]
38. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J
AIDS; 2016 Jun; 30(10):1597-606. PubMed ID: 26950313
[TBL] [Abstract][Full Text] [Related]
39. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
Winston A; Mandalia S; Pillay D; Gazzard B; Pozniak A
AIDS; 2002 Oct; 16(15):2087-9. PubMed ID: 12370512
[TBL] [Abstract][Full Text] [Related]
40. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.
Antoniou T; Park-Wyllie LY; Tseng AL
Pharmacotherapy; 2003 Jan; 23(1):29-43. PubMed ID: 12523458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
